LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.2

Max

1.22

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Aktsiakasum	-0.43
Kasumimarginaal	-2,190.837
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+143.9% upside

Turustatistika
By TradingEconomics
Turukapital	-26M 76M
Eelmine avamishind	1.21
Eelmine sulgemishind	1.21

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. dets 2025, 17:29 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19. dets 2025, 16:47 UTC

Suurimad hinnamuutused turgudel

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19. dets 2025, 16:10 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

20. dets 2025, 19:00 UTC

Tulu

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

19. dets 2025, 22:33 UTC

Tulu

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19. dets 2025, 22:19 UTC

Tulu

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19. dets 2025, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 21:44 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 21:38 UTC

Tulu

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19. dets 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19. dets 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19. dets 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19. dets 2025, 18:00 UTC

Market Talk

Tulu

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19. dets 2025, 17:41 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 17:24 UTC

Market Talk

Tulu

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19. dets 2025, 16:29 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19. dets 2025, 16:20 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19. dets 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19. dets 2025, 16:18 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19. dets 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. dets 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19. dets 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 16:04 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19. dets 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

143.9% tõus

12 kuu keskmine prognoos

Keskmine 3 USD 143.9%

Kõrge 4 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.